The FDA approved: the weight loss drug is also designed to reduce heart attacks and strokes - voila! health. By treating obesity, we know we can reduce cardiovascular risk, and that may be only part of the cumulative benefits.
The approval is based on a study of 17,000 patients that showed people taking Vigobi, the better-known sister drug to Ozampic, had a 20% lower risk for a cardiac event compared to those taking a placebo. "The point is that these drugs are not about looks, but about health," said Dr. Harlan Krumholtz, a cardiologist and scientist at Yale University and Yale New Haven Hospital.